Patients

Researchers analyzed data from more than 5000 chronic pain patients across 36 US states.

As Texas advances legislation to ban hemp-derived THC, HB 46 seeks to expand the state’s medical cannabis program, with several recent changes.

Here, we bring you our top five recent articles covering hemp restrictions in Alabama and Texas, data on medical cannabis patients and sleep apnea, FDA making psychedelics a top priority, and research on cannabis use and sperm quality.

The report includes data from enrolled patients on products purchased, benefits, and side effects.

The survey asked about patient cannabis use, openness to discussing cannabis as part of treatment plans, and perspectives on substance use of physicians.

The effect of orally ingested cannabis on information processing speed, sustained and divided attention, inhibitory control, and mental flexibility was measured.

The survey included responses from over one thousand medical cannabis patients, plus an analysis of trends in the medical cannabis market.

This month’s Healer webinar explored how recent cannabis policies impact patients, parents, and more.

The Alabama Medical Cannabis Commission made the announcement in its most recent meeting, intending to advance the state medical cannabis program.

In response to the recent announcement that the hearing concerning cannabis rescheduling had been delayed, Americans for Safe Access held a webinar discussing the impacts medical cannabis.

Kentucky launched its medical cannabis program on January 1, 2025, allowing patients with qualifying conditions to apply for ID cards.

Germany’s Cannabis Act (CanG) is beginning to transform the country's medical cannabis market, with potential opportunities to expand telemedicine, improve physician training, and enhancing accessibility in this rapidly growing industry.

The patient-centered organization announced its 2025 plans for medical cannabis at the national level.

Aspergillus, a genus of mold that is abundant in our environment, has become a significant concern in the cannabis industry, particularly due to the health risks it poses to consumers. This mold, which thrives in various environments, including soil, decaying vegetation, and even in the air, is not inherently dangerous to healthy individuals. However, its presence in cannabis flowers, whether during cultivation, processing, or storage, can lead to severe health risks, especially for immunocompromised individuals.

The researchers point out that it is important for clinicians to ask about CBD use to better advise patients and prevent potential drug interactions.

Overall, the survey revealed that people with chronic pain supported policies expanding medical cannabis access more than physicians.

The study surveyed cannabis patients across the country on their use and perceptions of cannabis use during cancer treatment.

As discussions about the federal scheduling of cannabis continue, efforts by medical cannabis advocates are intensifying. One such advocate is Americans for Safe Access (ASA), a nonprofit organization founded by patients for patients. Since 2002, ASA has been championing the rights of medical cannabis patients and has recently launched new campaigns and strategies to refocus attention on patient needs. In this interview, Steph Sherer, founder and president of ASA, reflects on past successes in medical cannabis advocacy, shares her perspective on recent cannabis and hemp policymaking, and outlines the next steps for advancing a unified medical cannabis message on Capitol Hill—a message that could bring about the changes patients have long awaited.

Americans for Safe Access, a medical cannabis patient advocacy organization, held a briefing on the final day of the comment period for the proposed rulemaking on cannabis.

In the second installment in this webinar series, Dr. Marion McNabb and Dr. Peter Grinspoon discuss implementation of cannabis as a harm reduction agent from a clinical perspective.

Americans for Safe Access, the nation’s largest member-based medical cannabis advocacy organization, held a webinar discussing the recent recommendation made by the Department of Health and Human Services to reschedule cannabis.

Don't miss these exciting speakers in the medical and psychedelics tracks at Cannabis Science Conference Fall taking place September 21-22, 2023 in Providence, Rhode Island!

Filmed onsite at Cannabis Science Conference Spring 2023, Kim Stuck, founder and CEO of Allay Consulting, shares her unique insights and experiences in the industry.

Hear what the business director of a cannabis testing facility has to say about the future of the cannabis industry!

This article features real-life stories from a cannabis patient as well as an on-the-ground cannabis nurse.

A United Kingdom study revealed an association between cannabis products, improved quality of life, and reduced opioid use in chronic pain patients.

Our sister publication, Oncology Nursing News recently published how cannabidiol oil may be useful in helping patients with breast cancer manage tamoxifen-related adverse effects.

Two Colorado-based hemp companies and one tobacco company are joining forces to pursue FDA-approval for a new botanical drug.

A Washington State House Committee recently amended and then approved a psilocybin bill which will benefit patients.

Senate Bill 47, legalizing medical cannabis, was signed into law in March 2023 by Kentucky Governor Andy Beshear (D).